1. Home
  2. UVV vs CAPR Comparison

UVV vs CAPR Comparison

Compare UVV & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

HOLD

Current Price

$52.49

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$34.79

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVV
CAPR
Founded
1886
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
1994
2011

Fundamental Metrics

Financial Performance
Metric
UVV
CAPR
Price
$52.49
$34.79
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$44.63
AVG Volume (30 Days)
156.6K
1.0M
Earning Date
05-28-2026
05-12-2026
Dividend Yield
6.33%
N/A
EPS Growth
N/A
N/A
EPS
3.02
N/A
Revenue
$2,922,924,000.00
N/A
Revenue This Year
$0.67
N/A
Revenue Next Year
$0.10
$3.31
P/E Ratio
$17.16
N/A
Revenue Growth
7.40
N/A
52 Week Low
$49.96
$4.30
52 Week High
$67.33
$40.37

Technical Indicators

Market Signals
Indicator
UVV
CAPR
Relative Strength Index (RSI) 49.32 65.37
Support Level $51.37 $22.09
Resistance Level $53.87 $36.49
Average True Range (ATR) 0.91 2.05
MACD -0.03 0.31
Stochastic Oscillator 55.91 85.63

Price Performance

Historical Comparison
UVV
CAPR

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: